Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: Retrospective study (STACCATO)

Pharmacotherapy

Volumn 34, Issue 12, 2014, Pages 1250-1258

  Panisset, Michel ^a   Chen, Jack J ^b   Rhyee, Sean H ^c   Conner, Jill ^d   Mathena, Julie ^d  

^a NOTRE DAME HOSPITAL   (Canada)

^b LOMA LINDA UNIVERSITY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d Teva Neuroscience Inc   (United States)

Author keywords

antidepressants; depression; Parkinson disease; parkinsonism; rasagiline

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; RASAGILINE; SELEGILINE; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; INDAN DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CAUCASIAN; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EMERGENCY WARD; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 4 CLINICAL TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; SEROTONIN TOXICITY SYNDROME; TREATMENT DURATION; ADVERSE DRUG REACTION; COHORT ANALYSIS; DRUG INTERACTION; MIDDLE AGED; UNITED STATES;

AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COHORT STUDIES; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 84919871925     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1500     Document Type: Article

References (28)

1. Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG,. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008; 23: 183-9.
2. Chen JJ, Marsh L,. Depression in Parkinson's disease: identification and management. Pharmacotherapy 2013; 33: 972-83.
3. Troeung L, Egan SJ, Gasson N,. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease. PLoS ONE 2013; 8: e79510.
4. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl 3): S42-80.
5. Chen JJ, Swope DM, Dashtipour K,. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 2007; 29: 1825-49.
6. Hoy SM, Keating GM,. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. Drugs 2012; 72: 643-69.
7. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937-43.
8. Olanow CW, Rascol O, Hauser R, et al.; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-78.
9. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-54.
10. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62: 241-8.
11. Chen JJ,. Pharmacologic safety concerns in Parkinson's disease: facts and insights. Int J Neurosci 2011; 121 (Suppl 2): 45-52.
12. Goren T, Adar L, Sasson N, Weiss YM,. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol 2010; 50: 1420-8.
13. Azilect [package insert]. Kansas City, MO: Teva Neuroscience, Inc.; 2009.
14. Boyer EW, Shannon M,. The serotonin syndrome. N Engl J Med 2005; 352: 1112-20.
15. Chan BS, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG,. Serotonin syndrome resulting from drug interactions. Med J Aust 1998; 169: 523-5.
16. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM,. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96: 635-42.
17. Martin TG,. Serotonin syndrome. Ann Emerg Med 1996; 28: 520-6.
18. Pedavally S, Fugate JE, Rabinstein AA,. Serotonin syndrome in the intensive care unit: clinical presentations and precipitating medications. Neurocrit Care 2014; 21: 108-13.
19. Speiser Z, Fine T, Litinetsky L, Eliash S, Blaugrund E, Cohen SJ,. Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline. J Neural Transm 2008; 115: 107-16.
20. Hilli J, Korhonen T, Laine K,. Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1526-32.
21. Montgomery EB, Panisset M,. Retrospective analysis of the incidence of serotonin toxicity in patients taking rasagiline and antidepressants in clinical trials. Mov Disord 2009; 24 (Suppl 1): 359 (abstract).
22. Ghosh P, Winslow J, Musleh C, Gandhy C, Bahroo L, Pagan F,. The tolerability of rasagiline when used concurrently with serotonin reuptake inhibitors in Parkinson's disease: a retrospective analysis. Mov Disord 2010; 25 (Suppl 2): S400 (abstract).
23. Chhabria N, Ghosh P, Bahroo L, Pagan F,. A "real world" view of the tolerability of rasagiline with anti-depressants in Parkinson's disease: a retrospective study. Neurology 2011; 76 (Suppl 4): A485-6 (abstract).
24. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. Available from http://www.wma.net/en/30publications/10policies/b3/index.html. Updated October 22, 2008. Accessed May 14, 2014.
25. ICH GCP. International Conference on Harmonisation. Good Clinical Practice. Available from http://ichgcp.net/. Accessed March 12, 2014.
26. U.S. Food and Drug Administration. Code of Federal Regulations Title 21. Available from http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=50. Updated April 1, 2010. Accessed May 14, 2014.
27. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 1997; 48: 1070-7.
28. World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2011, 14th ed. Available from http://www.whocc.no/filearchive/publications/2011guidelines.pdf. Accessed May 14, 2014.